Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Porcellini

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Therapeutic Advances in Medical Oncology|December 5, 2019
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLCMarika Cinausero, Noemi Laprovitera, Giovanna De Maglio, et al.
Thrombosis and Haemostasis|December 21, 2019
Particulate Shiga Toxin 2 in Blood is Associated to the Development of Hemolytic Uremic Syndrome in ChildrenMaurizio Brigotti, Xiaohua He, Domenica Carnicelli, et al.
Molecular Oncology|June 2, 2021
MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primaryNoemi Laprovitera, Mattia Riefolo, Elisa Porcellini, et al.
Cellular Microbiology|December 23, 2018
The structure of the Shiga toxin 2a A-subunit dictates the interactions of the toxin with blood componentsMaurizio Brigotti, Dorothea Orth-Höller, Domenica Carnicelli, et al.
Iscience|July 31, 2025
An antibiotic derivative as a new potential tool in the prevention of hemolytic uremic syndromeElisa Varrone, Luciano Consagra, Domenica Carnicelli, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 21, 2024
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primaryAndrea Cavazzoni, Irene Salamon, Claudia Fumarola, et al.
Neurobiology of Aging|January 12, 2011
Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populationsJean-Charles Lambert, Diana Zelenika, Mikko Hiltunen, et al.
Nature Genetics|September 8, 2009
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's diseaseJean-Charles Lambert, Simon Heath, Gael Even, et al.
Journal of Alzheimer'S Disease : JAD|September 18, 2010
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis studyJean-Charles Lambert, Kristel Sleegers, Antonio González-Pérez, et al.
Nature Genetics|April 5, 2011
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's diseasePaul Hollingworth, Denise Harold, Rebecca Sims, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Therapeutic Advances in Medical Oncology|December 5, 2019
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLCMarika Cinausero, Noemi Laprovitera, Giovanna De Maglio, et al.
Thrombosis and Haemostasis|December 21, 2019
Particulate Shiga Toxin 2 in Blood is Associated to the Development of Hemolytic Uremic Syndrome in ChildrenMaurizio Brigotti, Xiaohua He, Domenica Carnicelli, et al.
Molecular Oncology|June 2, 2021
MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primaryNoemi Laprovitera, Mattia Riefolo, Elisa Porcellini, et al.
Cellular Microbiology|December 23, 2018
The structure of the Shiga toxin 2a A-subunit dictates the interactions of the toxin with blood componentsMaurizio Brigotti, Dorothea Orth-Höller, Domenica Carnicelli, et al.
Iscience|July 31, 2025
An antibiotic derivative as a new potential tool in the prevention of hemolytic uremic syndromeElisa Varrone, Luciano Consagra, Domenica Carnicelli, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 21, 2024
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primaryAndrea Cavazzoni, Irene Salamon, Claudia Fumarola, et al.
Neurobiology of Aging|January 12, 2011
Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populationsJean-Charles Lambert, Diana Zelenika, Mikko Hiltunen, et al.
Nature Genetics|September 8, 2009
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's diseaseJean-Charles Lambert, Simon Heath, Gael Even, et al.
Journal of Alzheimer'S Disease : JAD|September 18, 2010
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis studyJean-Charles Lambert, Kristel Sleegers, Antonio González-Pérez, et al.
Nature Genetics|April 5, 2011
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's diseasePaul Hollingworth, Denise Harold, Rebecca Sims, et al.
Pageof 5